Literature DB >> 18355488

Measuring follow-up completeness.

YingXing Wu1, Johanna J M Takkenberg, Gary L Grunkemeier.   

Abstract

Completeness of follow-up is often used as a measure of the quality of follow-up, but the method used to compute it is often not declared. An ideal measure should be based on follow-up years instead of patients. Clark, Altman, and De Stavola proposed such a measure, called "C", which is the percentage of the maximum possible follow-up years, as of a given date, that has actually been accounted for or observed. However, such a measure will underestimate the true completeness, because the denominator (maximum possible follow-up years) does not account for unobserved patient deaths occurring before that date, and therefore, it is realistically unachievable. We propose a modification, C*, of Clark's C, which accounts for the effect of unobserved patient deaths in attenuating the maximum potential follow-up, and thus gives a higher percentage for achieved follow-up completeness. We validated this theoretical improvement by comparing the values of C and C* computed for our long-term coronary artery bypass graft patients to the true completeness, which was obtained by using the National Death Index to complete our missing follow-up data. Using Clark's C, the follow-up completeness was 80.4% and using our C* it is 84.5%, whereas the true follow-up completeness based on National Death Index information was 85.0%.

Entities:  

Mesh:

Year:  2008        PMID: 18355488     DOI: 10.1016/j.athoracsur.2007.12.012

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  14 in total

1.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  BMC Med       Date:  2012-05-29       Impact factor: 8.775

2.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

3.  Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.

Authors:  Brian I Rini; Susan Halabi; Jonathan E Rosenberg; Walter M Stadler; Daniel A Vaena; Laura Archer; James N Atkins; Joel Picus; Piotr Czaykowski; Janice Dutcher; Eric J Small
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

4.  Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.

Authors:  Donna Niedzwiecki; Monica M Bertagnolli; Robert S Warren; Carolyn C Compton; Nancy E Kemeny; Al Bowen Benson; S Gail Eckhardt; Steven Alberts; Gity N Porjosh; David J Kerr; Anthony Fields; Philippe Rougier; J Marc Pipas; Joel H Schwartz; James Atkins; Mark O'Rourke; Michael C Perry; Richard M Goldberg; Robert J Mayer; Thomas A Colacchio
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

5.  Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.

Authors:  Kimmie Ng; Shuji Ogino; Jeffrey A Meyerhardt; Jennifer A Chan; Andrew T Chan; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; Al B Benson; Paul L Schaefer; Renaud Whittom; Alexander Hantel; Richard M Goldberg; Monica M Bertagnolli; Alan P Venook; Charles S Fuchs
Journal:  J Natl Cancer Inst       Date:  2011-08-17       Impact factor: 13.506

6.  Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803.

Authors:  Kimmie Ng; Jeffrey A Meyerhardt; Jennifer A Chan; Donna Niedzwiecki; Donna R Hollis; Leonard B Saltz; Robert J Mayer; Al B Benson; Paul L Schaefer; Renaud Whittom; Alexander Hantel; Richard M Goldberg; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2010-08-30       Impact factor: 44.544

7.  Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803.

Authors:  Nadine Jackson McCleary; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al Benson; Richard Goldberg; Jeffrey A Meyerhardt
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

8.  Differential losses to follow-up that are outcome-dependent can vitiate a clinical trial: Simulation results.

Authors:  Richard F Potthoff
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

9.  Association of family history with cancer recurrence and survival among patients with stage III colon cancer.

Authors:  Jennifer A Chan; Jeffrey A Meyerhardt; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; James Thomas; Paul Schaefer; Renaud Whittom; Alexander Hantel; Richard M Goldberg; Robert S Warren; Monica Bertagnolli; Charles S Fuchs
Journal:  JAMA       Date:  2008-06-04       Impact factor: 56.272

10.  The association between continuity of care in the community and health outcomes: a population-based study.

Authors:  Jacob Dreiher; Doron S Comaneshter; Yael Rosenbluth; Erez Battat; Haim Bitterman; Arnon D Cohen
Journal:  Isr J Health Policy Res       Date:  2012-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.